• Title/Summary/Keyword: 최신 지견

Search Result 178, Processing Time 0.024 seconds

Recent Advances in Regulating Energy Homeostasis and Obesity (에너지 항상성 조절 및 비만의 병태생리에 관한 최신지견)

  • Park, Mi Jung
    • Clinical and Experimental Pediatrics
    • /
    • v.48 no.2
    • /
    • pp.126-137
    • /
    • 2005
  • New insights in the complex metabolic pathways and its control mechanism for energy homeostasis have refined our understanding of the pathophysiology of obesity. It is now recognized that there are several additional regulatory mechanism such as peripheral signals including leptin, ghrelin, GLP-1 and PYY and cellular signals including uncoupling proteins and ${\beta}$ Adrenergic receptors, which contribute to the regulation of food intake and energy expenditure, respectively. In addition, the function of adipocyte as an endocrine organ in energy homeostasis has been recently emphasized. Recent findings suggest that elevated levels of adipokines, such as leptin, adiponectin, resistin and TNF-${\alpha}$, in addition to increased free fatty acid level could be related to the pathophysiology of insulin resistance in obesity. For effective treatments and prevention of obesity, further studies on the circuits of neural and endocrine interactions in the regulation of energy homeostasis are needed.

Current Updates in the Treatment of Achilles Tendon Rupture (아킬레스건 파열 치료에 대한 최신 지견)

  • Kim, Jun-Beom;Yoon, Ja-Yeong
    • Journal of Korean Foot and Ankle Society
    • /
    • v.23 no.3
    • /
    • pp.83-90
    • /
    • 2019
  • Achilles tendon rupture is a common sports injury encountered in younger populations. Various treatment methods are used for acute and chronic rupture. Several treatments for each condition are available, each having their advantages and disadvantages. In an acute rupture, surgical treatment may be a priority for younger patients or those wishing a quick return to play, but the long-term functional outcome is similar to non-surgical treatment. In addition, the re-rupture rate shows a slight difference between the two treatments. The clinical outcomes are similar regardless of the surgical treatment, but an accelerated rehabilitation program should be accompanied by good results. In chronic and neglected rupture, surgical treatment is preferred over non-surgical treatment. Treatments are chosen based on the size of the tendon defect. This article reviews the current updates in the treatment of Achilles tendon rupture that will help clinicians choose the appropriate treatment.

Update on Tuberculosis in Children and Adolescents (소아청소년의 결핵 감염과 질병에 대한 최신 지견)

  • Kim, Jong Hyun
    • Pediatric Infection and Vaccine
    • /
    • v.16 no.2
    • /
    • pp.107-114
    • /
    • 2009
  • Tuberculosis is a disease with high morbidity and mortality in children worldwide. Despite significant improvements in diagnostic methods, scientific researches and clinical trials for new regimens of treatment or prevention in adult tuberculosis, childhood tuberculosis has been relatively neglected. Children are at high risk of severe disease, and reactivation of latent infection in adulthood perpetuates the epidemic. Therefore, a policy of tuberculosis control in childhood should be emphasized to improve control in the total population. To understand the new view of childhood tuberculosis, this article describes changes in the disease's national epidemiology, new diagnostic tools and treatment strategies, and multi-drug resistance.

  • PDF

Update of Pathophysiology in GERO/LPR (위식도역류질환과 인후두역류질환의 대한 최신지견)

  • Woo, Jeong-Sao
    • Korean Journal of Bronchoesophagology
    • /
    • v.16 no.2
    • /
    • pp.83-90
    • /
    • 2010
  • The pathophysiology of Gastroesophageal reflux disease (GERD) has been known that it is developed when the offense-primarily the gastric acid-pepsin content of the refluxate-overcomes a 3-tiered esophageal protective defense. consisting of antireflux mechanisms, luminal clearance mechanisms, and tissue resistance. Laryngopharyngeal reflux (LPR), which is known as an extraesophageal variant of GERD, has been considered to be developed by transient lower esophageal sphincter relaxation (TLESR), direct mucosal injury by gastric contents, more sensitive mucosa compared to esophagus, and absence of buffering effect and aggravation of the injury due to pepsin. However, hypothesis of the pathophysiology in both entities are numerous and still lack of understanding for being a theory. There is no conflict that understanding the pathophysiology is necessary for resolving the problems of these diseases and numerous studies and results have been releasing. This review could provide clinicians dealing with GERD and LPR with applicable new information and help for overcoming the clinical obstruction.

  • PDF

Update on Medical Treatment of GERD/LPR (위식도역류질환과 인후두역류질환의 약물 요법에 대한 최신지견)

  • Kim, Mi-Na;Kim, Joo-Sung
    • Korean Journal of Bronchoesophagology
    • /
    • v.16 no.2
    • /
    • pp.97-104
    • /
    • 2010
  • Gastroesophageal reflux disease (GERD) is a common disorder caused by the reflux of gastric contents into the esophagus. According to the recent classification, GERD can elicit esophageal and extraesophageal syndromes. Laryngopharyngeal reflux (LPR) is defined as laryngeal symptoms with laryngeal inflammation caused by the acid reflux. The prevalence of GERD and LPR is increasing during the past decades in Korea and management of GERD and LPR is a challenging issue in clinical practice. Proton pump inhibitor is the most effective drug in the treatment of GERD. Most patients with LPR are given a 2-month trial of a proton pump inhibitor (PPI), however, there is still little evidence on the diagnosis or the treatment of LPR. During the last years concern have been raised regarding the risk of averse events related to long-term use of PPI. We review the recent update on medical treatment of GERD/LPR.

  • PDF

Modafinil for the Treatment of Attention Deficit Hyperactivity Disorder: A Systematic Review (Modafinil의 주의력결핍 과잉행동장애 치료효과에 대한 체계적 문헌 고찰)

  • Lee, Yu-Jeung
    • Korean Journal of Clinical Pharmacy
    • /
    • v.20 no.1
    • /
    • pp.66-71
    • /
    • 2010
  • 주의력결핍 과잉행동장애는 미국에서 약 200만 명의 어린이에게 나타나는 심각한 만성 신경행동학적 장애이다. 주의력결핍 과잉행동장애 치료의 중심은 약물요법이다. 그러나 현재 환자의 약 30%는 주의력결핍 과잉행동장애를 적응증으로 갖도록 허가된 의약품들을 사용해도 적절한 치료효과를 얻지 못하고 있는 상황이다. Modafinil은 methylphenidate나 amphetamines와 같은 각성제와는 다른 약리학적 기전으로 중추신경계를 항진시킨다. 본 연구는 modafinil의 주의력결핍 과잉행동장애 치료효과에 대한 최신 지견을 얻고자, 1990년부터 2010년 3월까지 MEDLINE에 등재된 논문을 ADHD와 Modafinil이라는 MeSH terms로 검색하여 추출한 자료 중에서 대조군이 사용된 무작위 배정 및 이중맹검 임상연구 사례만을 선별하여 임상적 유용성을 평가하였다. 현재 modafinil은 주의력결핍 과잉행동 장애 치료제로 허가된 의약품은 아니지만 최근 여러 국가에서 시행된 연구들은 modafinil이 안전하고 효과적인 주의력결핍 과잉행동장애 치료제일 수 있다는 결과를 보여주고 있다.

Recent Trends of Sedation in Pediatric Dentistry (임상가를 위한 특집 3 - 소아치과에서 진정치료의 신경향)

  • Lee, Gi-Seop
    • The Journal of the Korean dental association
    • /
    • v.47 no.11
    • /
    • pp.736-749
    • /
    • 2009
  • 근래 환자의 불안을 조절하는 것이 성공적인 치료에 매우 중요하다는 인식이 확산되면서 의과, 치과, 영상의학과, 응급실 및 외래 수술센터 등에서 진정요법에 대한 필요가 현저하게 늘어났다. 응급상황이거나 아니거나 진정요법의 필요성은 점차 증가하고 있고 대한 소아치과학회는 이러한 진정요법에 대한 지침을 출간한 바 있다. 이번 개정은 진정요법에 필요한 적절한 환자감시(monitoring)의 필요에 관한 최신지견을 반영한 것이나 그럼에도 불구하고 이 지침에 충실하였다고 해서 특정환자의 결과를 보장하지는 못한다. 그러 나 이번에 소개하는 진정요법 protocol은 널리 받아들여지는 것으로 부작용 역시 최소화한 것이다. 소아 환자의 진정요법은 원하는 수준의 진정이나 투여 방법과는 상관없이 호흡기능 저하와 환자의 방어 반응이 소실될 수도 있다는 인식하에 작성되었다. 이번 호에서는 최근 2006년에 미국소아과학회와 미국소아치과학회가 공동으로 개정된 지침(Guideline for Monitoring and Management of Pediatric Patients During and After Sedation for Diagnostic and Therapeutic Procedures developed and endorsed by AAP a and AAPD)이 어떻게 변경되는지에 중점적으로 알아보며 새로 변경된 지침에 따라 소아치과의의 진정요 법의 진료와 교육도 영향을 미칠 것이다. 이러한 영향으로 다양한 약 투여방법(Alternative routes of d drug administration)과 다양한 약물의 선택에 대해 알아 보기로 한다.

  • PDF

비만의 약물요법에 대한 최신 지견

  • 이선영
    • Proceedings of the Korean Society of Applied Pharmacology
    • /
    • 2001.04a
    • /
    • pp.3-30
    • /
    • 2001
  • 비만은 고혈압, 제2형 당뇨병, 지방간, 고지혈증, 퇴행성관절염, 일부 암성 질환 등 다양한 만성 퇴행성 질환들을 유발할 수 있으므로 비만을 하나의 질환으로 인식하고 치료할 필요가 있다. 비만은 식사요법, 운동요법과 행동수정요법을 병행해야 최상의 치료효과를 거둘 수 있다고 알려져 왔지만, 비만 치료가 끝나고 4년 후에 빠진 체중의 절반만이라도 다시 늘지 않고 유지하고 있는 사람은 10-30%에 불과하다. 그러나 비만 문제가 중요하고 현재까지의 치료방법이 성공적이지 못함에도 불구하고 비만의 약물 치료의 적절성에 대해서는 논란이 있다. 그러나 최근 비만의 약물 치료에 대해 재평가가 이루어지고 있으며, 식사, 운동, 행동요법과 약물치료의 병합 요법이 효과가 있음을 입증하는 연구결과들이 보고되고 있다. 여기에서는 비만증의 진단기준과 치료원칙을 간단히 설명하고 비만증의 약물요법을 위주로 살펴보도록 하겠다.

  • PDF

Recent Advances in Radioiodine Therapy for Thyroid Cancer (갑상샘암의 방사성요오드 치료의 최신 지견)

  • Bae, Sang-Kyun
    • Nuclear Medicine and Molecular Imaging
    • /
    • v.40 no.2
    • /
    • pp.132-140
    • /
    • 2006
  • Well-differentiated thyroid cancer is the most common endocrine malignancy with an increasing incidence. Most patients with well-differentiated thyroid caner have a favorable prognosis with high survival rate. While surgery and radioiodine therapy is sufficient treatment for the majority of patients with differentiated thyroid cancer, a minority of these patients experiences progressive, life-threatening growth and metastatic spread of the disease. Because there is no prospective controlled study to evaluate the differences of management of thyroid cancer, it is hard to choose the best treatment option. And there are still lots of controversies about the management of this disease, such as surgical extent, proper use of radioiodine for remnant ablation and therapy, use of rhTSH instead of withdrawal of thyroid hormone, long-term follow-up strategy, thyroglobulin as a tumor marker, etc. In this review, recent data related to these conflicting issues and recent advances in diagnosis, radioiodine therapy and long-term monitoring of well-differentiated thyroid cancer are summarized.

Recent Advances in Anti-Obesity Agents (비만 약물 치료의 최신 지견)

  • Kim, Min Kyung;Kim, Chul Sik
    • The Korean Journal of Medicine
    • /
    • v.93 no.6
    • /
    • pp.501-508
    • /
    • 2018
  • Obesity is a chronic disorder that is a significant risk factor for diabetes, cardiovascular diseases, malignancy, and other chronic diseases. Lifestyle modifications form the basis of most treatments for obesity, but it has become clear that such modifications alone are not enough for many obese patients. When a behavioral approach is insufficient, pharmacological treatment may be recommended. In recent years, the US Food and Drug Administration (FDA) has withdrawn several therapeutic options for obesity due to their side effects, but has approved four novel anti-obesity agents. Until recently, orlistat was the only drug approved for the management of long-term obesity, but the US FDA approved the novel anti-obesity drugs lorcaserin and phentermine/topiramate in 2012, and naltrexone/bupropion and liraglutide in 2014. The present review discusses the different pharmacotherapeutic options for the treatment of obesity.